Lupin to file application for biosimilar etanercept in EU, Japan in next quarter

YL Biologics, a JV of Lupin and Japanese firm Yoshindo, says phase-III trial of Etanercept met the primary endpoint and the product's safety and immunogenicity was found to be similar to the reference drug Enbrel